Next Article in Journal
Correction: Alexandre-Gouabau et al. “Comprehensive Preterm Breast Milk Metabotype Associated with Optimal Infant Early Growth Pattern”, Nutrients, 2019, 11, 528
Previous Article in Journal
Role of Resveratrol in Transmitochondrial AMD RPE Cells
Previous Article in Special Issue
P-Glycoprotein 1 Affects Chemoactivities of Resveratrol against Human Colorectal Cancer Cells
Open AccessArticle

Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial

1
Department of Endocrine and Metabolic Diseases, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr 987514763448, Iran
2
Canadian Centre for Agri-Food Research in Health and Medicine, Winnipeg, MB R2H 2A6, Canada
3
Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
4
Agriculture and Agri-Food Canada, Winnipeg, MB R3T 2M9, Canada
*
Authors to whom correspondence should be addressed.
Nutrients 2020, 12(1), 161; https://doi.org/10.3390/nu12010161
Received: 1 November 2019 / Revised: 23 November 2019 / Accepted: 4 December 2019 / Published: 6 January 2020
(This article belongs to the Special Issue Resveratrol and Its Analogs in Human Diseases)
Resveratrol has been reported to be beneficial against diabetes complications. The objective of this study was to evaluate the efficacy of resveratrol in decreasing hyperglycemia in patients with type 1 diabetes (T1D) by a preliminary investigation designed as an exploratory clinical trial. Thirteen patients with T1D from both the sexes participated in this trial. All patients received resveratrol in 500 mg capsules, twice daily for 60 days. Bodyweight, fasting blood sugar (FBS), hemoglobin A1c (HbA1c), insulin, homeostasis model of assessment for insulin resistance (HOMA-IR), homeostasis model of assessment for β-cell function (HOMA-β), and markers of liver and kidney damage, inflammation, and oxidative stress were measured before the intervention, at 30 days and at 60 days. Resveratrol supplementation for 60 days significantly decreased FBS and HbA1c in comparison with the baseline values. Resveratrol treatment also resulted in a decrease in the level of a marker for oxidative stress, malondialdehyde, and an increase in total antioxidant capacity in T1D patients. Insulin, HOMA-IR, HOMA-β, and markers of liver and kidney function and inflammation were not significantly affected by resveratrol treatment. Overall, the results showed that 60 days of resveratrol supplementation exerted strong antidiabetic and antioxidant effects in patients with T1D. View Full-Text
Keywords: resveratrol; type 1 diabetes; hyperglycemia; hemoglobin A1c; oxidative stress resveratrol; type 1 diabetes; hyperglycemia; hemoglobin A1c; oxidative stress
Show Figures

Figure 1

MDPI and ACS Style

Movahed, A.; Raj, P.; Nabipour, I.; Mahmoodi, M.; Ostovar, A.; Kalantarhormozi, M.; Netticadan, T. Efficacy and Safety of Resveratrol in Type 1 Diabetes Patients: A Two-Month Preliminary Exploratory Trial. Nutrients 2020, 12, 161.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop